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Abstract
Background: Transplantation of neural stem cells (NSCs) is a promising novel approach to the treatment of
neuroinflammatory diseases such as multiple sclerosis (MS). NSCs can be derived from primary central nervous system
(CNS) tissue or obtained by neural differentiation of embryonic stem (ES) cells, the latter having the advantage of readily
providing an unlimited number of cells for therapeutic purposes. Using a mouse model of MS, we evaluated the therapeutic
potential of NSCs derived from ES cells by two different neural differentiation protocols that utilized adherent culture
conditions and compared their effect to primary NSCs derived from the subventricular zone (SVZ).
Methodology/Principal Findings: The proliferation and secretion of pro-inflammatory cytokines by antigen-stimulated
splenocytes was reduced in the presence of SVZ-NSCs, while ES cell-derived NSCs exerted differential immunosuppressive
effects. Surprisingly, intravenously injected NSCs displayed no significant therapeutic impact on clinical and pathological
disease outcomes in mice with experimental autoimmune encephalomyelitis (EAE) induced by recombinant myelin
oligodendrocyte glycoprotein, independent of the cell source. Studies tracking the biodistribution of transplanted ES cell-
derived NSCs revealed that these cells were unable to traffic to the CNS or peripheral lymphoid tissues, consistent with the
lack of cell surface homing molecules. Attenuation of peripheral immune responses could only be achieved through
multiple high doses of NSCs administered intraperitoneally, which led to some neuroprotective effects within the CNS.
Conclusion/Significance: Systemic transplantation of these NSCs does not have a major influence on the clinical course of
rMOG-induced EAE. Improving the efficiency at which NSCs home to inflammatory sites may enhance their therapeutic
potential in this model of CNS autoimmunity.
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Introduction
Therapeutic transplantation of neural stem/precursor cells
(NSCs) is currently being investigated as a novel treatment
strategy for multiple sclerosis (MS) and other neurodegenerative
diseases [1]. Although originally based on the concept of cell
replacement, evidence emanating from studies in experimental
autoimmune encephalomyelitis (EAE), an animal model which
mimics many features of MS, has revealed little evidence for the
remyelinating capacity of transplanted NSCs. Rather, the
improved clinical outcome appears to result from bystander
immunomodulatory and neuroprotective effects, exerted by NSCs
in response to signals from the surrounding microenvironment,
which collectively dampen inflammation, inhibit glial scar
formation and enhance neurogenesis [2,3,4,5]. Importantly for
the treatment of multifocal diseases such as MS, systemically
injected NSCs have been reported to not only regulate immune
responses in peripheral lymphoid tissues [5,6,7], but also migrate
across the blood brain barrier into the CNS parenchyma [4,5].
Although the molecular mechanisms governing NSC homing from
the vasculature to sites of CNS pathology remain undefined,
expression of molecules important in leukocyte trafficking are
thought to play an important role [8].
Despite these encouraging pre-clinical studies, several outstand-
ing issues surrounding the clinical translation of NSC-based
therapies still remain unresolved, including the optimal dose, route
of transplantation and cell source. EAE transplantation studies
have predominantly focused on primary mouse NSCs derived
from neurogenic regions of the brain. While human fetal NSCs
have already been used in clinical trials [9], these cells may not
represent a suitable cell source for large scale therapeutic
transplantation [10]. Alternatively, embryonic stem (ES) cells, or
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provide an unlimited source of NSCs for cell-based therapies. The
protocols used for neural differentiation of ES cells have
traditionally involved propagation of neurospheres [11], which
are highly heterogeneous floating cell clusters comprised of a small
number of NSCs in addition to progenitors with limited
differentiation potential. In order to overcome problems associated
with the heterogeneity of neurosphere cultures, a protocol to
derive and expand NSCs in the presence of basic fibroblast growth
factor (bFGF) and epidermal growth factor (EGF) via niche
independent adherent monocultures has been developed, allowing
large scale production of uniform, symmetrically renewing NSCs
with a tri-lineage differentiation potential [12,13,14].
The ability of ES cell-derived NSCs to undergo migration and
differentiation when transplanted directly into the developing or
adult brain has been described in numerous studies [13,15,16,17],
however much less is known about their therapeutic efficacy in
neuroinflammatory disease models such as EAE, particularly when
delivered by a systemic route. The current study sought to evaluate
the therapeutic effect of systemically administered NSCs derived
from ES cells in a chronic progressive murine model of MS
induced by recombinant myelin oligodendrocyte glycoprotein
(rMOG). We chose to focus on NSCs derived by two different ES
cell differentiation protocols that utilize adherent culture condi-
tions. 46C-NS cells are a homogenous, symmetrically dividing
NSC population derived from ES cells in the presence of bFGF
and EGF, while GS-N cells are comprised of a heterogeneous
population of progenitor cells similar in composition to neuro-
spheres. As a further comparison, we have utilized NSCs derived
from the subventricular zone of adult mice (SVZ-NSCs), which are
expanded using the free floating neurosphere system. We show
that only GS-N cells and SVZ-NSCs can effectively suppress both
T-cell proliferative responses and pro-inflammatory cytokine
production in vitro, however the homing efficiency of systemically
administered cells limits the efficacy NSC transplantation in this
model of CNS autoimmunity.
Results
Characterization of neurally differentiated ES cells
Previous reports have described the differentiation of mouse ES
cells into uniform and symmetrically dividing NSCs using serum-
free adherent monocultures [12,13]. 46C-NS cells are one well
characterized NSC line derived from Sox1-green fluorescent
protein (GFP) knock in reporter ES cells [12]. Confirming results
presented in earlier studies, we found that 46C-NS cells uniformly
expressed nestin (Fig. 1A) and the radial glia marker 3CB2
(Fig. 1B), which recognizes three isoforms of vimentin [18], but not
the astrocytic marker glial fibrillary acidic protein (GFAP) (Fig. 1A)
or neuronal marker microtubule-associated protein-2 (MAP2)
(Fig. 1B). Under appropriate differentiation conditions 46C-NS
cells demonstrated a neuronal and astrocytic differentiation
potential, as determined by positive staining for bIII-tubulin and
MAP2 (Fig. 1C) and GFAP (Fig. 1D).
We next developed a protocol for neural differentiation of ES
cells, with the aim of generating a heterogeneous population of
NSCs and progenitor cells that could be grown under adherent
culture conditions, as opposed to employing the free-floating
neurosphere culture system. Embryoid bodies (EBs) were first
derived from ES cells via the spin EB method [19] and then
cultured in non-adherent 96-well plates for 7 days (Fig. 2A). These
EBs could be used to generate neurospheres (Fig. 2B) or could be
mechanically dissociated and re-plated onto poly-L-ornithine/
laminin coated plates for 4 days to generate adherent cells termed
GS-N cells (Fig. 2C). In order to verify neuroectodermal
specification, the gene expression profile of these cells was
examined by quantitative real time PCR. The transcription factor
Oct4, a marker of pluripotency, was downregulated in day 7 EBs,
day 4 neurospheres and day 4 GS-N cells compared to ES cells
(Fig. 2D). In contrast, the neuroectodermal marker nestin was
upregulated in EBs, GS-N cells and to a lesser extent in
neurospheres. Interestingly, while expression of the neuronal
markers b-III tubulin and MAP2 also increased during neural
induction, only GS-N cells showed highly upregulated expression
of GFAP. Transcripts for 29,39-cyclic nucleotide 39-phosphodies-
terase, an enzyme almost exclusively expressed by myelinating
cells [20], could also be detected in GS-N cells by RT-PCR (data
not shown), while expression of genes marking the mesodermal
and endodermal germ lineages were not detected (Fig. 2E).
Immunofluorescence further confirmed that the GS-N cells
were comprised of a heterogeneous population of neural
progenitors and lineage restricted cells expressing nestin (Fig. 3A),
the oligodendrocyte progenitor marker A2B5 (Fig. 3B) and bIII-
tubulin and MAP2 (Fig. 3C). To promote neuronal differentiation,
GS-N cells were cultured for an additional two weeks in the
absence of growth factors. Under these conditions, increased
numbers of mature MAP2
+NeuN/Fox-3
+ neuronal cells were
generated (Fig. 3D). Alternatively, when GS-N cells were exposed
to serum to promote astrocytic differentiation, substantial numbers
of GS-N cells adopted an astrocytic morphology and expressed
GFAP (Fig.3E). Quantitative analyses revealed that these differ-
entiated cultures contained 69.28%66.14 GFAP
+ cells.
To demonstrate that functional neural cell types could be
generated using our ES cell differentiation protocol, the electro-
physiological properties of neuronally differentiated GS-N cells
were assessed by making patch-clamp recordings in whole-cell,
current clamp mode. These cells had resting membrane potentials
of 26362 mV, input resistances of 1.460.3 GV, and input
capacitances of 2562 pF. The neuronal cells that formed dense
networks with many interconnecting processes (Fig. 3F) were
found to fire action potentials (APs) spontaneously (Fig. 3G, H),
with amplitudes of 8167 mV and width at half amplitude of
2.760.8 ms. Spontaneous APs occurred in 69% of cells and were
Figure 1. Characterization of 46C-NS cells. (A–C) Immunofluores-
cence staining showed 46C-NS cells expressed nestin, red (A) and 3CB2,
red (B) but not GFAP, green (A) or MAP2, green (B). (D–E) Following
neuronal or astrocytic differentiation, 46C-NS cells expressed bIII-
Tubulin, red and MAP2, green (C) or GFAP (D), respectively.
doi:10.1371/journal.pone.0035093.g001
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+ channel blocker tetrodotoxin (TTX)
(Fig. 3G). APs occurred due to the development of spontaneous
depolarisations, which took the membrane potential beyond the
threshold for the opening of TTX-sensitive voltage-gated Na
+
channels (Fig. 3G, H). Study of these spontaneous events in voltage
clamp, and in the presence of TTX to prevent APs, revealed the
underlying inward currents (Fig. 3I). Notably, cells with limited
network connections to other cells (Fig. 3J) generated smaller and
less frequent depolarisations, and hence fired few spontaneous
APs. Although no APs occurred spontaneously in 31% of cells,
APs could be evoked by depolarising current steps and these had
characteristics that were indistinguishable from APs that occurred
spontaneously (Fig. 3K). Collectively, these results demonstrate
that our differentiation protocol could yield a heterogeneous
population of adherently growing cells, which expressed markers
representative of all three neural lineages and could be further
differentiated into functional neurons.
GS-N cells and 46C-NS cells exert differential effects on T-
cells in vitro
Attenuation of inflammatory processes within the CNS and
peripheral lymphoid tissues is an important mechanism by which
NSCs mediate clinical recovery in EAE [5,6,7,21]. To directly
compare their immunosuppressive potential in an antigen-specific
setting, varying numbers of GS-N cells or 46C-NS cells were co-
cultured with fixed numbers of splenocytes from 2D2 mice, which
express the transgenic Va3.2/Vb11 T-cell receptor specific for the
encephalitogenic myelin oligodendrocyte glycoprotein (MOG)35–
55 peptide [22]. We also simultaneously assessed the immunosup-
pressive properties of SVZ-NSCs propagated by the neurosphere
Figure 2. Gene expression profile of GS-N cells. (A) ES cells aggregated to form round floating EBs. (B) Day 4 neurospheres with neural
projections generated from EBs. (C) Day 4 GS-N cells generated by dissociation of EBs. (D–E) Quantitative real time PCR analysis of the expression of
neuroectodermal genes (D) and mesodermal and endodermal genes (E) by ES cells, day 7 EBs, day 4 neurospheres and day 4 GS-N cells. cDNA from
embryonic heart tissue and Activin A (ActA) treated EBs served as positive controls.
doi:10.1371/journal.pone.0035093.g002
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employed for studying NSC transplantation in EAE and other
CNS disease models. GS-N cells suppressed T-cell proliferative
responses to MOG35–55 in a dose-dependent manner, with
significant inhibition observed at stem cell:splenocyte ratios of
1:2 and 1:10 (Fig. 4A). The immunosuppressive capacity of GS-N
cells was comparable to SVZ-NSCs at high cell numbers (ratio 1:2,
45.2%64.3 vs 53.1%65.7 T-cell inhibition, respectively), however
GS-N cells were significantly less efficient at inhibiting T-cell
proliferation compared to SVZ-NSCs at lower cell numbers (ratio
1:10, 25.5%64.6 vs 52.6%67.8 T-cell inhibition, respectively).
Nevertheless, the immunosuppressive capacity of GS-N cell was
significantly more potent than 46C-NS cells, which exerted no
inhibitory effect on T-cell proliferative responses at any of the
ratios tested.
To analyze the effect of GS-N cells, 46C-NS cells and SVZ-
NSCs on cytokine production by MOG35–55-stimulated spleno-
cytes, supernatant was collected from co-cultures in which
maximal inhibition of T-cell proliferation was observed (ratio
1:2). The levels of key cytokines known to play a role in EAE
pathogenesis [23] were then quantified by cytometric bead array.
Production of the pro-inflammatory cytokines interferon (IFN)-c,
tumor necrosis factor (TNF)-a, interleukin (IL)-2, IL-17A and IL-6
was reduced when MOG35–55-stimulated splenocytes were co-
cultured with GS-N cells or SVZ-NSCs (Figs. 4B–F). Unexpect-
edly, 46C-NS cells also inhibited the secretion of these cytokines,
despite the fact that T-cell proliferative responses were unaffected.
Moreover, IL-4 production by stimulated splenocytes was reduced
in the presence of GS-N cells but not 46C-NS cells or SVZ-NSCs
(Fig. 4G), suggesting that different mechanisms of action may
underlie the immunosuppressive properties of these cells. Taken
together, SVZ-NSCs appear to exhibit the most potent suppressive
capacity in vitro, however all three cell types have the capacity to
reduce the secretion of cytokines known to mediate inflammatory
processes in EAE.
Intravenously injected NSCs do not attenuate rMOG-EAE
We next evaluated the therapeutic efficacy of GS-N cells, 46C-
NS cells and SVZ-NSCs in chronic-progressive EAE induced by
rMOG, a model in which both T- and B-cells contribute
pathogenetically [24,25]. Three intravenous (i.v.) injections of
1610
6 cells were administered to EAE mice 8, 10 and 12 days post
disease induction, at a time when the blood brain barrier is open.
Surprisingly, none of the NSC-treated groups displayed a delay in
the onset of clinical signs compared to PBS-injected controls (GS-
N cells: 13.2560.49, 46C-NS cells: 13.1460.77, SVZ-NSC:
15.5762.60, PBS: 14.2960.57). Furthermore, no difference in
the mean daily clinical score (Fig. 5A) or other disease metrics,
such as the cumulative disease score or maximum clinical score,
was observed. Spleens were then dissected on day 31 post disease
induction in order to assess the impact of NSC transplantation on
peripheral T-cell responses. Consistent with the clinical data, re-
call proliferation assays showed that the proliferative response of
splenocytes to MOG35–55 and non-specific mitogens was similar
between the three NSC-treated groups and controls (Fig. 5B).
Inefficient recruitment to sites of inflammation reduces
the efficacy of GS-N cell transplantation
The absence of a beneficial effect in EAE mice following NSC
therapy, despite the ability to suppress immune responses in vitro,
could be due to the inefficient recruitment of transplanted cells to
peripheral lymphoid tissues and areas of neuroinflammation. This
Figure 3. Differentiation potential of GS-N cells. (A–C) Immunofluorescence staining showed GS-N cells expressed nestin, red (A), A2B5, red (B)
and bIII-Tubulin, red and MAP2, green (C). (D–E) Following neuronal or astrocytic differentiation, GS-N cells expressed MAP2, green and NeuN, red (D)
or GFAP (E), respectively. (F–K) Electrophysiological assessment of GS-N cell-derived neurons. Neurons in high density (F) fired spontaneous action
potentials (APs), which were blocked by tetrodotoxin (TTX) (G). The depolarization giving rise to the APs (H) was underpinned by an inward current (I).
Sparsely growing neurons (J) did not display spontaneous activity but APs could be evoked by depolarising current steps (K).
doi:10.1371/journal.pone.0035093.g003
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pulmonary capillaries, as demonstrated previously for NSCs [26],
and/or the lack of appropriate surface receptor expression and
inability to actively home to inflamed tissues. To investigate this,
we derived GS-N cells from GFP
+ ES cells in order to track their in
vivo biodistribution by PCR. The detection limit for this assay,
determined by titrating varying amounts of DNA from GFP
+ GS-
N cells with DNA obtained from EAE mice, was found to be 1 ng
of GFP
+ DNA, which corresponded to 150 GFP
+ cells (Fig. 5C). At
day 12 post disease induction (the onset of clinical disease), GFP
+
GS-N cells or mouse embryonic fibroblasts (MEFs) as a control cell
type, were injected i.v. into EAE mice and various tissues were
collected for analysis 24 hrs later. Transplanted GS-N cells could
not be detected within the CNS or secondary lymphoid tissues,
and only in one instance could the presence of GFP
+ cells be
identified within the lungs of EAE mice (data not shown). Analysis
of the biodistribution of GFP
+ GS-N cells during the chronic stage
of disease (23 days post injection) revealed that GFP
+ cells were
only present in the kidney but not in the CNS, secondary
lymphoid organs or lungs (Fig. 5D). These results suggest that GS-
N cells were unable to migrate to and engraft at inflammatory
sites, thus contributing to their lack of efficacy following i.v.
transplantation into EAE mice.
The molecular mechanisms governing the recruitment and
migration of NSCs from the vasculature to inflamed sites are not
yet well defined, but are likely to involve adhesion molecules and
chemokine receptors that are important for leukocyte homing,
such as very late antigen-4 (VLA-4; integrin-a4b1) [8]. Flow
cytometric analysis showed that GS-N cells lacked surface
expression of several adhesion molecules, namely the hyaluronic
acid receptor CD44, integrin-a2, integrin-a4 and integrin-a5
whereas both integrin-b1 and integrin-a6 were expressed (Fig. 6A).
In contrast, 46C-NS cells constitutively expressed varying levels of
CD44 and all five integrins (Fig. 6B), indicating that these cells
may have a greater capacity for adhesion and migration across
inflamed endothelium compared to GS-N cells. SVZ-NSCs
expressed CD44, integrin-b1, integrin-a2, integrin-a4 and inte-
grin-a6 but lacked expression of integrin-a5 (Fig. 6C). Surprising-
ly, the SDF-1a receptor CXCR4, which has been implicated in
targeted recruitment of cells to the CNS [27] as well as mediating
their firm adhesion to brain endothelium [28], was not expressed
on the surface of any of our three NSC types. Thus, the absence of
homing molecules may have contributed to the limited therapeutic
potential of NSCs in rMOG-induced EAE.
Figure 4. Suppression of in vitro MOG-specific T-cell responses. (A) Fixed numbers of splenocytes from 2D2 mice stimulated with MOG35–55
were cultured in the presence of varying numers of GS-N cells, 46C-NS cells or SVZ-NSCs (expressed as NSC: splenocyte ratio). Proliferative responses
were measured by
3H-thymidine incorporation and expressed as the mean counts per minute (CPM). (B–G) Supernatants were collected from co-
cultures after 48 hrs and the level of pro-inflammatory cytokines was quantified by cytometric bead array. Data represent the mean 6 SEM (n=4
mice). *P,0.05, **P,0.01, ‘P,0.005,
#P,0.001 vs MOG35–55 stimulated splenocytes unless otherwise indicated.
doi:10.1371/journal.pone.0035093.g004
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myelin oligodendrocyte glycoprotein and treated with intravenous injections of GS-N cells, 46C-NS cells or SVZ-NSCs on days 8, 10 and 12 post
immunization. (B) Proliferative response of splenic T-cells from cell-treated mice and controls to rMOG and non-specific mitogens expressed as the
mean counts per minute (CPM). Data are expressed as the mean 6 SEM (n=5–7 mice). (C) Decreasing amounts of DNA from GFP
+ GS-N cells were
titrated with DNA extracted from EAE mice and the minimum amount of GFP
+ DNA detectable was determined by PCR using primers specific for GFP.
(D) GFP
+ GS-N cells or fibroblasts were injected intravenously into EAE mice at 12 days post disease induction and PCR was used to detect GFP
+ cells.
PCR reactions performed without DNA served as a negative control and DNA from C57Bl/6-GFP chimeric mice served as a positive control.
doi:10.1371/journal.pone.0035093.g005
Figure 6. Cell surface expression of homing molecules. Flow cytometric analysis was used to examine cell surface expression of homing
molecules by GS-N cells (A), 46C-NS cells (B) and SVZ-NSCs (C). Representative histograms are shown in grey and respective isotype controls are
indicated by the black curve.
doi:10.1371/journal.pone.0035093.g006
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Previous studies have shown that intraperitoneally (i.p.)
delivered mesenchymal stem cells are capable of attenuating
EAE [29,30,31], providing insight into peripheral immunomod-
ulatory mechanisms that mediate their therapeutic effect whilst
avoiding passive entrapment of transplanted cells within the
pulmonary capillary bed. Subcutaneously injected NSCs can
inhibit T-cell priming within the lymph nodes of EAE mice when
transplanted prior to the onset of clinical signs [32], however the
impact of i.p. injected NSCs on the course of EAE has not yet been
determined. To test the feasibility of this delivery route we initially
transplanted SVZ-NSCs, as these cells demonstrated the most
potent immunosuppressive properties in vitro, as well as MEFs as a
control cell type. When 1610
6 cells were administered i.p. at days
8, 10 and 12 post disease induction, mice receiving SVZ-NSCs
displayed a reduced mean daily clinical score compared to PBS-
injected controls and a significant reduction compared to MEF-
treated mice (Fig. 7A). On the basis of these results, we chose to
administer a higher dose (5610
6 cells per injection) to test the
efficacy of i.p. injected GS-N cells and 46C-NS cells. In this
experimental setting, GS-N cell-treated mice showed a significant
decrease in disease severity during the chronic stage (days 27–33)
compared with PBS-injected controls (Fig. 7B). Furthermore, GS-
N cell treatment led to a reduction in the cumulative disease score
as well as a significant reduction in the maximum clinical score
(p=0.0249, Table 1). Despite the high number of cells
transplanted, 46C-NS cells failed to show any significant impact
on the disease course.
Histopathological evaluation of haematoxylin and eosin stained
spinal cord sections from PBS-treated mice showed typical
extensive mononuclear inflammatory cell infiltration (Fig. 7C).
Luxol fast blue (Fig. 7D) and Bielschowsky silver staining (Fig. 7E)
also showed marked myelin loss and axonal injury, respectively. In
comparison, GS-N cell-treated animals displayed reduced inflam-
mation (Fig. 7F) with an associated preservation of the myelin
architecture (Fig. 7G) and significantly reduced axonal damage
(Fig. 7H, Table 1). Interestingly and despite the fact that 46C-NS
cell-treatment did not alter the clinical course of disease,
inflammatory infiltrates in the CNS of these mice were
significantly reduced (Fig. 7I, Table 1). A trend towards reduced
demyelination and axonal damage was also observed (Fig. 7J, K).
Transplanted GS-N cells and 46C-NS cells suppress
peripheral T-cell responses
To determine whether the reduction in CNS pathology of NSC-
treated mice was due to suppression of peripheral immune
responses, we first performed re-call proliferation assays to assess
the ex vivo proliferative response of splenic T-cells to specific and
non-specific mitogens. Although no significant difference in
rMOG-specific T-cell responses was observed, there was a
significant decrease in T-cell proliferation when splenocytes from
GS-N and 46C-NS cell-treated mice were re-stimulated with anti-
CD3/CD28 (GS-N cells: p=0.0035; 46C-NS cells: p=0.0011 vs
PBS) or phorbol myristate acetate and ionomycin (GS-N cells:
p=0.0171; 46C-NS cells: p=0.0035 vs PBS; Fig. 7L). Quantifi-
cation of cytokine levels in anti-CD3/CD28 stimulated cultures
showed that splenocytes from GS-N cell-treated mice produced
significantly less IFN-c, TNF-a and IL-2 (Fig. 7M–O) and reduced
levels of IL-17A (Fig. 7P). Likewise, the level of these pro-
inflammatory cytokines was also reduced for mice receiving 46C-
NS cells. We further analyzed the effect of GS-N cells and 46C-NS
cells on autoantibody production, however no significant differ-
ence in serum levels of rMOG-specific antibodies was found
(Fig. 7S). Taken together, these results suggest that high numbers
of GS-N cells or 46C-NS cells could suppress peripheral T-cell
responses in a non-specific manner, leading to some neuroprotec-
tive effects within the CNS.
Discussion
Ex vivo expanded NSCs derived from neurogenic regions of the
brain possess an inherent therapeutic plasticity [33]. Indeed,
clinical recovery has been induced by NSC transplantation in
experimental models of traumatic brain injury, stroke, Parkinson’s
disease, Huntington’s disease, spinal cord injury and MS. The
mechanisms which mediate amelioration of EAE occur predom-
inantly through bystander immunomodulatory and neuroprotec-
tive effects exerted by NSCs, rather than differentiation and
functional integration in the CNS [34]. A critical issue for the
successful clinical application of ES cells in CNS diseases is the
ability to efficiently generate purified NSCs with this same
therapeutic plasticity.
Numerous methods involving manipulation of the extrinsic
culture environment, via the addition of various growth factors
and modulation of signaling pathways, to induce neural specifi-
cation of mouse and human ES cells have been described [35].
Although NSCs have been traditionally cultured as neurospheres,
a more recent method has employed niche independent adherent
culture conditions to generate uniform and symmetrically dividing
NSCs [13], thereby avoiding the heterogeneity that develops
within the neurosphere structure [36]. In the current investigation,
we confirmed some of the phenotypic properties and the
differentiation potential of 46C-NS cells described previously
[13,14]. Utilizing our own ES cell differentiation protocol, we
generated a heterogeneous population of adherently cultured
progenitor cells that expressed markers representative of all three
neural lineages. Our electrophysiological assessment of GS-N cells
undergoing neuronal differentiation confirmed that functional
neural cell types could indeed be generated from this protocol.
The characteristics of these neurons were similar to those reported
for neurons in brain slices [37], in freshly isolated neurons [38], in
neurons derived from human embryonic stem cells [39] and in
neurons reprogrammed from fibroblasts [40]. Signaling networks
are known to be critical for normal functioning of the nervous
system [41]. Interestingly, we demonstrate here that the signaling
networks formed by neuronally differentiated GS-N cells were also
important for their functional properties, as action potentials
occurred spontaneously when the density of neurons was higher
and rarely occurred in neurons that were not close to each other.
Transplanted NSCs exert their therapeutic effect in part via
non-specific immunosuppression [7,21], which led us to compare
the impact of GS-N cells and 46C-NS cells on in vitro T-cell
proliferative responses as a prelude to transplantation studies. The
ability of GS-N cells to inhibit T-cell proliferation was similar to
that of SVZ-NSCs propagated via the neurosphere system at high
cell numbers, whereas 46C-NS cells had remarkably little effect.
The individual cell types within the heterogeneous neurosphere
structure that account for the immunosuppressive properties of
NSCs, as demonstrated by SVZ-NSCs in this study and by others
[2,7,42], have not been extensively analyzed. Yet, the differenti-
ation potential can influence the immunosuppressive properties of
neural cell types, as astrocytes but not neurons are capable of
suppressing T-cell responses in vitro [2,43]. Furthermore, some
adherent NSC cultures have a higher neuronal potential [44],
which may limit their immunosuppressive capacity. An extensive
analysis of methods for neural differentiation of ES cells and how
these may influence the functional properties of NSCs was beyond
the scope of this study. Thus, we have instead focused on a
Neurally Differentiated Stem Cells for MS
PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e35093comparison of NSCs derived from ES cells by two different neural
differentiation protocols that utilize adherent culture conditions,
resulting in either a symmetrically dividing population (46C-NS
cells) or heterogeneous population more reminiscent of neuro-
spheres (GS-N cells). Whilst the uniformity of NSC cultures such
as 46C-NS cells may be desirable, for instance to reduce
experimental variability, it is interesting to note that in current
setting, only heterogeneous NSC cultures were capable of
suppressing T-cell proliferation. Nevertheless, secretion of pro-
inflammatory cytokines IFN-c, IL-2, TNF-a and IL-17 was
reduced in the presence of GS-N cells and 46C-NS cells.
Moreover, 46C-NS cells did not suppress the production of IL-
4, which is associated with disease remission in EAE. Thus, ES
cell-derived NSCs in general may have the potential to modify the
cytokine secretion profile of immune cells, which could certainly
exert a major influence on clinical outcomes in EAE [45] and
possibly other neuroinflammatory conditions.
Systemically delivered primary NSCs have been shown to traffic
to the CNS not only in EAE [4,5,46,47], but also in mouse models
of stroke [48] and Huntington’s disease [49]. While the survival,
migration and integration of neural differentiated ES cells injected
directly into the CNS has been reported during development [15]
Figure 7. Effect of intraperitoneal NSC transplantation on the clinical course of EAE. C57Bl/6 mice were immunized with recombinant
myelin oligodendrocyte glycoprotein and treated with intraperitoneal injections of NSCs on days 8, 10 and 12 post immunization. (A) EAE mice
received 1610
6 SVZ-NSCs or MEFs. Data are expressed as the mean clinical score 6 SEM (n=5 mice). (B) EAE mice received 5610
6 GS-N cells or 46C-
NS cells. Data are expressed as the mean clinical score 6 SEM (n=9–10 mice). Arrows indicate days of injection. (C–K) Representative spinal cord
sections of PBS control mice (C–E), GS-N cell-treated mice (F–H), or 46C-NS cell-treated mice (I–K) were stained with haematoxylin and eosin, luxol fast
blue and Bielschowsky silver stain to detect inflammation, demyelination and axonal damage, respectively. Magnification 6400. (L) Proliferative
response of splenic T-cells from cell-treated mice and controls to rMOG and non-specific mitogens expressed as the mean counts per minute (CPM).
(M–R) Supernatant from rMOG-stimulated splenocyte cultures were collected after 48 hrs and cytokines were quantified by cytometric bead array. (S)
Serum rMOG-specific antibody response from NSC-treated mice and controls. Data are expressed as the mean 6 SEM (n=9–10 mice). *P,0.05,
**P,0.01, ‘P,0.001 versus PBS controls,
#P,0.05.
doi:10.1371/journal.pone.0035093.g007
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paucity of information regarding their capacity to respond to tissue
signals when delivered systemically. This study was therefore
performed to assess whether neural differentiated ES cells could
produce the same therapeutic effect that has been reported for
NSCs derived from CNS tissue. We were unable to find any
beneficial effect on the clinical course of disease after multiple i.v.
injections of GS-N cells or 46C-NS cells were administered to mice
with rMOG-induced EAE. Moreover, SVZ-NSCs did not
attenuate EAE severity, which is in contrast to previous studies,
in which substantial clinical recovery could be induced after a
single i.v. injection of primary NSCs, irrespective of whether the
cells were delivered before [4,5,7] or after [4,5,46,47] disease
onset. The influence of GS-N cells, 46C-NS cells and SVZ-NSCs
on EAE induced by MOG35–55 is currently under investigation.
The reasons for these discrepancies are not readily apparent but
could possibly be due to the low numbers of transplanted NSCs
reaching inflammatory sites. Tracking the fate of GFP
+ GS-N cells
administered i.v. to EAE mice by PCR revealed that cells could
only be detected in the lungs 24 hrs post injection. While this is in
line with a previous report tracking the fate of NSCs in stroke [53],
Pluchino and colleagues [5] reported that within 24 hrs of
injection, primary NSCs had accumulated in the CNS. Similarly,
the presence of primary NSCs could be detected in the spleen and
lymph nodes within 2 hrs and up to 24 hrs post injection [7].
Using the cuprizone model of demyelination, Crocker et al. [54]
also recently reported that ES cell-derived NSCs could traffic to
the CNS and reduce demyelination when injected i.v. To allow
time for migration into tissues the biodistribution of GS-N cells
was assessed at a later time point during the chronic stage of
disease, however GS-N cells were not detected in the CNS or in
secondary lymphoid tissues. Although we did detect the presence
of GFP
+ cells in the kidney, this was likely to be due to the removal
of cellular debris rather than the directed migration of the
transplanted cells. The lack of a therapeutic effect of 46C-NS cells
supports recent findings by Reekmans et al. [26], in which
bioluminescent-based cell tracking studies revealed that adherently
expanded NSCs were retained in the lungs following i.v.
administration and demonstrated no clinical benefit on the course
of EAE. Likewise, it is possible that in the present study, i.v.
injected NSCs may have accumulated in the lungs of EAE mice
and undergone apoptosis.
We also tested, for the first time, the therapeutic effect of i.p.
delivered NSCs as a means of targeting immune responses in the
periphery. The reduced pathogenic potential of splenic T-cells in
mice receiving high numbers of i.p. injected GS-N cells or 46C-NS
cells, as observed in re-call proliferation and cytokine secretion
assays, led to some neuroprotective effects within the CNS. In spite
of this, we observed no significant impact of 46C-NS cell
transplantation on the clinical course of the disease. Moreover,
significant amelioration of disease in GS-N cell-treated mice was
only observed during the chronic stage of disease. Our results
suggest that NSCs may not have been capable of engrafting within
peripheral lymphoid organs and mediating long-term clinical
recovery when delivered by an i.p. route. Alternatively, the
immunosuppressive effects exerted by transplanted NSCs at this
time in the disease course, when autoreactive immune cells have
already entered the CNS, may not have been sufficient to
overcome ongoing neuroinflammatory and degenerative process-
es. The microenvironment plays an important role in providing
extracellular cues that determine the fate and survival capacity of
stem cells. Thus, the death of transplanted cells shortly after
injection [55,56] may have been a further contributing factor to
the limited therapeutic efficacy of i.p. delivered NSCs, despite the
high dose administered. It is also noted that 46C-NS cells and GS-
N cells exhibited no impact on serum autoantibody levels. Given
differences in the pathogenesis of rMOG-induced EAE versus
EAE induced by the encephalitogenic MOG35–55 peptide,
particularly with regard to the role of B-cells [24,25], further
examination of the immunoregulatory properties of NSCs is
required.
In addition to the ability to modulate immune responses, the
homing efficiency of systemically transplanted NSCs to sites of
inflammation and tissue injury appears to be critically important in
this model of CNS autoimmunity. Cellular trans-endothelial
migration is orchestrated by a complex group of adhesion
molecules, chemokines and their receptors, which permits tissue-
specific migration of particular cell types [57]. Flow cytometric
analysis revealed that GS-N cells lacked cell surface expression of a
number of key homing molecules, including CD44 and integrin-
a4. Accumulating evidence indicates that lymphocyte homing to
the CNS requires CD44 and integrin-a4 for initial rolling and firm
adhesion of lymphocytes to inflamed endothelium [57]. Notably,
blocking antibodies against CD44 and integrin-a4 have been
shown to inhibit lymphocyte recruitment into the CNS during
EAE [58]. Antibodies directed against integrin-a4 were also found
to decrease recruitment of NSCs to the brain and spinal cord
following systemic delivery [5]. Rampon et al. [59] further
demonstrated that the interaction between CD44 and hyaluronic
acid also plays a crucial role in the migration of NSCs across brain
endothelium under in vitro inflammatory conditions. While 46C-
NS cells and SVZ-NSCs were found to express CD44 and
Table 1. Clinical and pathological outcome of EAE mice.
PBS control GS-N cells 46C-NS cells
Disease incidence 11/11 9/10 8/10
Day disease onset (range) 19.6461.75 (12–32) 22.4062.53 (15–36) 22.2062.69 (13–36)
Maximum score 3.0960.18 2.4560.32* 2.5060.42
Cumulative score 50.5066.98 32.5067.41 40.0267.70
Inflammatory score 2.4160.33 1.6560.39 1.3560.29*
Demyelinating score 2.3660.34 1.5060.37 1.4060.31
Axonal loss score 3.0060.36 1.5060.38** 1.9560.42
Data are expressed as mean 6 SEM.
*p,0.05,
**p,0.01 vs PBS.
doi:10.1371/journal.pone.0035093.t001
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expression of CXCR4. Chemokine receptor signaling pathways
provide important cues to direct the migration of cells during tissue
injury and inflammation [57]. Specifically, the CXCR4/SDF-1
signaling pathway is known to have an essential role during brain
development [60] and has been implicated in the recruitment of
lymphocytes and NSCs to sites of CNS pathology [27,28,61].
While surface expression of CXCR4 has been previously reported
on primary NSCs [5,61], the lack of CXCR4 expression observed
here may be the consequence of in vitro cell culture, as
demonstrated during ex vivo expansion of mesenchymal stem cells
[62].
In summary, we demonstrate that the NSCs used in this study,
either derived by neural differentiation of ES cells or isolated from
the SVZ of adult mice, did not have a major beneficial impact in
an EAE model of chronic progressive disease induced by rMOG.
Although the bystander immunosuppressive and immunomodu-
latory properties of NSCs are important, our results suggest that
the capacity for homing to inflammatory sites also appears to be a
key factor that influences the efficacy of NSCs in this model and
should be investigated further. Differences in the therapeutic
potential of ES cell-derived NSCs and primary NSCs are not
unexpected, given that gene expression analysis has previously
demonstrated differences between ES cell and fetal tissue-derived
NSCs [63]. Furthermore, extrinsic signals resulting from manip-
ulation of the cell culture environment may have a major impact
on the plasticity and function of NSCs [35]. Indeed, it is possible
that NSCs derived by other protocols [4,7], may demonstrate an
enhanced beneficial effect in rMOG-EAE. A more extensive
comparative analysis of the expression and function of cell surface
homing molecules, and how the migratory potential of NSCs may
be influenced by the culture environment, was beyond the scope of
this study. However, understanding the mechanisms controlling
NSC trafficking in neuroinflammatory diseases such as MS is
important and may enable these cells to be manipulated as means
of improving their homing efficiency, for instance by altering
extracellular matrix components during neural induction in order
to modulate integrin expression [64] or by enforcing the
expression of relevant homing, as demonstrated by ex vivo
modification of CD44 isoforms on MSCs to improve trafficking
to bone [65]. A careful examination of the trafficking potential of
NSCs should therefore be performed in parallel with the
development of protocols for neural differentiation and expansion
of NSCs in order for their full regenerative potential to be
exploited.
Materials and Methods
Cell culture
46C-NS cells obtained from StemCells Inc (Palo Alto, CA,
USA) were generated by neural conversion of 46C ES cells and
cultured as previously described [12,13]. For astrocytic differen-
tiation, 46C-NS cells were seeded in 4-well plates at 1610
5 cells/
cm
2 in RHB-A medium (StemCells Inc) supplemented with 1%
FBS (Invitrogen, Carlsbad, CA, USA) for one week. For neuronal
differentiation, 46C-NS cells were seeded in poly-L-ornithine
(Sigma, St Louis, MO, USA)/laminin (Invitrogen) treated wells at
5610
4 cells/cm
2 in RHB-A medium with bFGF (Chemicon,
Temecula, CA, USA) alone for the first 6 days and then
withdrawing bFGF for the final 8 days of culture. The W9.5
mouse ES cell line [66] used to generate GS-N cells was kindly
provided by Professor Stanley. Briefly, ES cells were cultured on
mitomycin c-inactivated MEFs on 0.1% gelatin (Sigma) coated 6-
well plates and maintained in DMEM supplemented with 15%
FBS, 50 U/ml penicillin, 50 mg/ml streptomycin, 2 mM L-
glutamine, 1% non-essential amino acids (all from Invitrogen),
1000 U/ml leukemia inhibitory factor (Chemicon) and 0.1 mM 2-
mercaptoethanol (Sigma). For EB formation, 250–500 ES cells
were added to non-adherent 96-well plates (Costar, Corning,
Lowell, MA, USA) in chemically defined medium [19], supple-
mented with 10 ng/ml bFGF (Chemicon). Medium was refreshed
on day 4 and then on day 7. EBs were transferred and cultured for
a further 4 days in adherent 96-well plates coated with 0.1%
gelatin/4 mg/ml laminin to generate neurospheres. In parallel,
EBs were dissociated mechanically and seeded at 1610
5 cells/cm
2
on 10 mg/ml poly-L-ornithine/4 mg/ml laminin coated flasks in
neural basal medium (Invitrogen) containing 1% B27, 1% N2
supplement, 2 mM L-glutamine, 1% ITS-G, 50 U/ml penicillin
and 50 mg/ml streptomycin (all from Invitrogen) and 10 ng/ml
bFGF for 4–6 days. Dissociated cells were termed GS-N cells and
were used for in vitro and in vivo studies. For neuronal
differentiation of GS-N cells, bFGF was withdrawn from
dissociated day 7 EBs for 14 days. For astrocytic differentiation,
dissociated day 7 EBs were seeded onto 12-well plates at 2610
5
cells/cm
2 in neural basal medium supplemented with 2% FBS for
7 days. SVZ-NSCs derived from the brains of adult OG2 Bl6
homozygous mice were cultured as described [67].
Immunocytochemistry
Cells were fixed with 4% paraformaldehyde for 10 min, washed
in PBS and blocked for 2 hr in PBS containing 10% normal goat
serum, 1% bovine serum albumin, 0.02% sodium azide (Sigma).
Cells were incubated with primary antibody overnight at 4uC and
then with the appropriate secondary conjugate. Following
antibody staining, 49, 6-diamidino-2-pheylindole (Invitrogen) was
used for nuclear counterstaining. The following primary antibod-
ies were used: mouse anti-nestin monoclonal antibody (1/100),
rabbit anti-GFAP polyclonal antibody (1/1000), rabbit anti-MAP2
polyclonal antibody (1/800) (all from Chemicon), mouse anti-bIII-
tubulin monoclonal antibody (1/800; Covance, Princeton, NJ,
USA), mouse anti-3CB2 monoclonal antibody (1/80) and mouse
anti-RC2 monoclonal antibody (1/80) (both from DSHB, Iowa
City, IA, USA). Mouse anti-A2B5 monoclonal antibody (1/20)
was produced by hybridomas. Secondary antibodies were Alexa
fluor 568-conjugated goat anti-mouse IgG (1/800), Alexa fluor
488-conjugated goat anti-rabbit IgG (1/800) (both from Invitro-
gen) and rhodamine conjugated goat anti-mouse IgM (Chemicon).
Fluorescence images were acquired using an Olympus Provis
AX70 microscope.
Gene expression analysis
Total RNA was extracted from 1610
6 cultured cells using a
High Pure RNA Isolation Kit (Roche) as per the manufacturer’s
instructions. cDNA was prepared from 0.5 mg of total RNA using
SuperScript III First-Strand Synthesis System RT-PCR Kit and
oligo (dT) primers (Invitrogen). Quantitative real time PCR
experiments were performed using the Light Cycler 480 Real
Time PCR System (Roche Applied Science) with Platinum SYBR
Green qPCR superMix-UDG (Invitrogen). The thermocycling
protocol included an initial cycle at 95uC for 2 min, followed by 40
cycles of PCR at either 95uC for 15 s, 50uC for 30 s and 68uC for
30 s for albumin or 95uC for 15 s, 54uCo r6 0 uC for 15 s and
68uC for 20 s for all other genes. Each sample was run in
experimental triplicate. The samples were adjusted to the
quantitative expression of b-actin from the same samples.
Embryonic heart and Activin A (ActA) treated EB cDNA were
used as positive controls. PCR for CNPase was performed using
Platinum Taq DNA Polymerase High Fidelity (Invitrogen) with
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and then 32 cycles of 94uC for 30 sec, 55uC for 30 sec and 68uC
for 30 sec followed by 68uC for 10 min. The PCR products were
resolved by electrophoresis in 2% agarose gels and the bands were
visualized with ethidium bromide under UV light. Primer pairs are
shown in Table 2.
Electrophysiology
Electrophysiological recordings were made using standard
whole-cell patch-clamp techniques and an Axopatch 200 amplifier
(Axon Instruments Inc, CA, USA). The coverslips from four
separate experiments containing cells were placed in a recording
chamber (Warner Instruments, Hamden, CT, USA) and contin-
uously superfused with physiological saline solution containing:
NaCl 137 mM, NaHCO3 4 mM, NaH2PO4 0.3 mM, KCl
5.4 mM, KH2PO4 0.44 mM, MgCl2 0.5 mM, MgSO4 0.4 mM,
glucose 5.6 mM, HEPES 10 mM, CaCl2 1.3 mM, at pH 7.4.
Patch electrodes were filled with solution containing; KCl
135 mM, MgCl2 1.2 mM, ATP 1 mM, EGTA 1 mM, HEPES
10 mM, pH 7.2. Data were digitized at 5–20 kHz with a 1 kHz
low-pass filter, stored on computer and analyzed using Clampfit
10 (Axon Instruments). Depolarizing current steps were used to
evoke action potentials. TTX (3 mm) was used to block voltage
gated Na
+ channels. All chemicals were purchased from Sigma.
Cell surface expression analysis
Phenotypic analysis by flow cytometry was performed by
staining 0.5610
6 cells with 30 ml of appropriately diluted primary
antibody for 20 min at 4uC. Where applicable, cells were stained
with 30 ml of streptavidin Alexa-fluor 647-conjugated secondary
antibody (Invitrogen). The relevant isotype control antibody was
used as a negative control. Cells were analyzed using a
FACSCanto II flow cytometer (BD) and data analyzed using
Gatelogic software (Inivai Technologies, Mentone, Victoria,
Australia). Primary antibodies were: CD29-FITC, CD44-APC,
CD49b-APC, CD49d-biotin, CD49e-biotin, CD49f-PE, CXCR4-
FITC (all from BD).
Recombinant MOG Purification
The extracellular domain of mouse MOG (amino acid residues
1–117 of the mature protein) (rMOG) was produced in the
Escherichia coli strain DH5alpha using the pQE9 expression vector
(QIAGEN) to incorporate an amino-terminal histidine tag as per
the manufacturer’s instructions. A clarified bacterial lysate
containing rMOG was loaded onto a Ni-NTA Superflow column
(QIAGEN) under denaturing conditions (6M Guanidine-HCl,
20 mM Tris, 500 mM NaCl, 5 mM Imidazole, pH 8.0) as per the
manufacturer’s instructions using a BioLogic LP chromatography
system (BioRad). Bound protein was washed sequentially with
Buffer A (8M Urea, 100 mM NaH2PO4, 10 mM Tris, pH 8.0),
Buffer A (at pH 6.3), Buffer A (at pH 8.0) and finally Buffer B
(10 mM Tris-Cl, pH 8). To remove endotoxin the protein was
washed by alternating between Buffer C (60% iso-propanol/
10 mM Tris-Cl, pH 8) and Buffer B twice each. The protein was
then washed in Buffer A again. Refolding of the bound protein was
carried out by applying a linear gradient of Buffer A containing
14 mM 2-mercaptoethanol (100%–0%) vs. Buffer D (100 mM
NaH2PO4, 10 mM Tris, pH 8.0, 1 mM reduced glutathione,
0.1 mM oxidised glutathione) (0%–100%). This was followed by a
second linear gradient of Buffer D (100%–0%) vs. Buffer E
(100 mM NaH2PO4, 10 mM Tris, pH 8.0) (0%–100%). The
bound protein was eluted using Buffer E containing 300 mM
Imidazole, and then extensively dialysed over 72 hr against
200 mM NaCl/10 mM Tris, pH 8.0. Protein concentration and
purity were estimated using an A280nm measurement and SDS-
PAGE, respectively. The protein produced was verified as rMOG
by western blot analysis using antibodies specific for native MOG.
EAE induction and cell transplantation
Chronic-progressive EAE was induced in 8–10 week old female
C57Bl/6 by subcutaneous injection of 75 mg rMOG emulsified in
complete Freund’s adjuvant (Sigma) supplemented with 400 mg
Mycobacterium tuberculosis (Difco, Detroit, MI, USA) into both hind
limb flanks. Mice immediately received an intraperitoneal
injection of 350 ng Bordetella pertussis toxin (Sigma) and again
48 hr later. For cell transplantation, cells were injected either i.v.
via the tail vein or into the peritoneal cavity in a volume of 200 ml
on days 8, 10 and 12 post immunization. Controls received
injections of equal volumes of D-PBS. Mice were monitored daily
and clinical scores were assigned according to an arbitrary clinical
scale as described [68]. Mice were humanely killed upon reaching
a clinical score of 4. All animal experimental procedures were
carried out in accordance with the animal ethics guidelines of the
National Health and Medical Research Council of Australia and
Table 2. Primer sequences used for gene expression analysis.
Target Forward Reverse Product size
Oct4 59-CGTTCTCTTTGGAAAGGTGTTC-39 59-GAACCATACTCGAACCACATCC-39 319 bp
Nestin 59-CCAGAGCTGGACTGGAACTC-39 59-ACCTGCCTCTTTTGGTTCCT-39 161 bp
bIII-tubulin 59-TCAGCGATGAGCACGGCATA-39 59-CACTCTTTCCGCACGACATC-39 301 bp
GFAP 59-ACCAAATCCGTGTCAGAAGG-39 59-CAGAAGGAAGGGAAGTGCTG-39 231 bp
MAP2 59-AGCCGCAACGCCAATGGATT-39 59-TTTGTTCTGAGGCTGGCGAT-39 313 bp
CNPase 59-CCAAATTCTGTGACTACGGG-39 59-GGTTTGCCCTTCCCATAGTA-39 448 bp
Nkx2-5 59-TCAAGCCCGAGGCCTACTCTGG-39 59-TGGTCTCTCGGCGCCATCCG-39 248 bp
Tbx5 59-GGAAAGATGAGGAATGTTCCAG-39 59-GTGTTACAGCTGATGTCCTCCA-39 223 bp
Myh6 59-ACGCCTAGAGGCCCAGACCC-39 59-CCGGCTCGTGCAGGAAGGTC-39 233 bp
Albumin 59-GCTACGGCACAGTGCTTG-39 59-CAGGATTGCAGACAGATAGTC-39 266 bp
Brachyury 59-CATGTACTCTTTCTTGCTGG-39 59-GGTCTCGGGAAAGCAGTGGC-39 313 bp
b-actin 59-CTGGCCGGGACCTGACAGACTACC-39 59-ATCGGAACCGCTCGTTGCCAATAG-39 228 bp
doi:10.1371/journal.pone.0035093.t002
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Biomedical Sciences Animal Ethics Committee (approval number
SOBSA/MIS/2006/37).
In vivo tracking of GFP
+ GS-N cells
Organs from EAE mice injected with GFP
+ GS-N cells, GFP
+
fibroblasts or non-injected EAE mice were dissected and genomic
DNA extracted using a Gentra Puregene Tissue Kit (QIAGEN,
Venlo, Netherlands) according to the manufacturer’s instructions.
PCR for GFP and the housekeeping gene b-actin was performed
with Platinum Pfx DNA Polymerase (Invitrogen) and 100 ng of
cDNA under the following cycling conditions: 94uC for 5 min and
then 35 cycles of 94uC for 30 sec, 65uC for 30 sec and 68uC for
30 sec followed by 68uC for 10 min. Primer pairs were GFP: 59-
TACGGCAAGCTGACCCTGAAGTTC-39,5 9-CGTCGTCC-
TTGAAGAAGATGGTGCG-39; b-actin: 59-GGCACCACACC-
TTCTACAATG-39,5 9-CGTCGTCCTTGAAGAAGATGGT-
GCG-39. The PCR products were resolved by electrophoresis in
2% agarose gels and the bands were visualized with ethidium
bromide under UV light.
Histological analysis of central nervous system tissue
For histological analysis of CNS tissue, the brain and spinal cord
were dissected from mice and fixed in 10% formalin (Sigma).
Serial sections (5 mm) were cut from paraffin-embedded tissues
and stained with H&E, luxol fast blue and Bielschowsky silver
impregnation to assess inflammation, demyelination and axonal
damage, respectively. Sections were scored blind for semi-
quantitative histological analysis of inflammation as follows: 0,
no inflammation; 1, cellular infiltrate only in the perivascular areas
and meninges; 2, mild cellular infiltrate in parenchyma; 3,
moderate cellular infiltrate in parenchyma; 4, severe cellular
infiltrate in parenchyma. Demyelination and axonal pathology
were assessed by pale staining and scored blind as follows: 0, no
demyelination/axonal pathology; 1, mild demyelination/axonal
pathology; 2, moderate demyelination/axonal pathology; 3, severe
demyelination/axonal pathology.
T-cell proliferation assays
Spleens were collected from 2D2 mice expressing the transgenic
Va3.2/Vb11 T-cell receptor specific for MOG5–55 peptide
(MEVGWYRSPFSRVVHLYRNGK) in the context of 1-A
b
[22] or rMOG-immunized mice. Single cell suspensions were
prepared in complete RPMI medium containing 10% heat-
inactivated FBS, 2 mM L-glutamine, 100 U/ml penicillin,
100 mg/ml streptomycin, 50 mM 2-mercaptoethanol and 1 mM
sodium pyruvate (Sigma). Following red blood cell lysis, spleno-
cytes were seeded in triplicate in 96-well, flat bottom microtiter
plates (Nunc) at a concentration of 2.5610
5 cells per well.
Splenocytes were cultured in medium alone or in the presence of
either 20 mg/ml MOG35–55 (GL Biochem, Shanghai, China),
20 mg/ml rMOG, 800 ng/ml ionomycin and 20 pg/ml PMA
(both from Sigma), or in wells pre-coated with 10 mg/ml anti-CD3
and 10 mg/ml anti-CD8 antibodies (both from BD). Cells were
incubated at 37uC for 72 hr with the addition of 1 mCi/well [
3H]-
thymidine (Perkin Elmer, Waltham, MA, USA) for the last 18 hr
of culture. Cells were harvested onto filter mats (Perkin Elmer) and
incorporated radioactive nucleic acids counted using a Top Count
NXT Scintillation Counter (Packard Biosciences, Meriden, CT,
USA). For co-culture experiments, GS-N cells, 46C-NS cells or
SVZ-NSCs were added at concentrations ranging from 0.01 to
1.25610
5 cells per well prior to the addition of splenocytes.
For analysis of cytokine production, 2.5610
6 splenocytes were
cultured in 24-well plates for 48 hours in medium alone or in the
presence of 20 mg/ml MOG35–55,2 0mg/ml rMOG, or in wells
pre-coated with anti-CD3 and anti-CD8 antibodies. For co-culture
experiments, 1.25610
6 GS-N cells, 46C-NS cells or SVZ-NSCs
were added. Quantitative analysis of IL-2, IL-17A, IFN-c and
TNF-a was performed using a mouse CBA kit (BD) according to
the manufacturer’s instructions. Acquisition of events was
performed on a BD FACSCanto II flow cytometer and data
analyzed and fitted to a 4-parameter logistic equation using the
FCAP array software (Soft Flow).
Anti-MOG antibody determination
Blood was collected at the end point of experiments by cardiac
puncture. The total serum antibody response against rMOG was
measured by enzyme-linked immunosorbent assay. Briefly, 96-well
plates (Nunc, Thermo Fischer Scientific, Roskilde, Denmark) were
coated with 100 ml of rMOG (5 mg/ml) in 0.05M carbonate buffer
(15 mM Na2CO3, 35 mM NaHCO3, pH 9.6) overnight at 4uC.
Wells were blocked with Pierce protein-free blocking medium
(Thermo Fischer Scientific) supplemented with 1.5% normal goat
serum for 3 hr at room temperature. For total rMOG-specific
antibody responses, 100 ml of serum was diluted 1/4000 in PBS.
Serum from naı ¨ve C57BL/6 mice was used as a negative control
and the monoclonal antibody 8-18C5 [69], diluted to 5 mg/ml was
used as a positive control. Antibody binding for total rMOG-
specific responses was revealed using a horseradish peroxidase-
conjugated goat anti-mouse antibody (Sigma) diluted 1/3000. O-
phenylenediamine (Sigma) was used as a substrate and the
reaction performed according to the manufacturer’s protocol.
Optical density (OD) was measured at 492 nm on a Benchmark
Plus Microplate Spectrophotometer (BioRad).
Statistical analysis
Experimental and control groups were compared using the
Student’s t test or the Kruskal Wallis with Dunn’s post-hoc test.
Results are expressed as mean 6 SEM. A value of P,0.05 was
considered statistically significant.
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